Nutrition and Cancer-An International Journal最新文献

The purpose of the study is to determine if artificial intelligence (AI) models could provide dietary recommendations to manage chemotherapy-induced nutritional symptoms in breast cancer (BC) patients that are on comparable levels with the American Cancer Society, National Cancer Institute and World Cancer Research Fund guidelines which were used as evidence-based recommendation. The AI models-ChatGPT, ChatGPT 4.0, Gemini, Gemini Advanced, Copilot, and Copilot Pro-were evaluated based on their adherence to the guidelines. Specific queries were posed to each model, and the generated responses were rated by two experienced dietitians using a 5-point likert scale. Gemini provided the most adherent recommendations for metallic taste in mouth, while Gemini Advanced excelled in managing dehydration. ChatGPT and Gemini Advanced were the most effective in addressing heartburn, and Copilot Pro consistently showed the lowest performance across most symptoms. Overall, ChatGPT 4.0 attained the highest total score, followed by Copilot and Gemini, indicating a general trend where certain models were better suited for specific symptoms. Various AI models (e.g. ChatGPT 4.0) show potential in addressing certain chemotherapy-induced symptoms, but they do not consistently align with evidence-based recommendations. Improvement of AI models is necessary for their adherence to evidence-based recommendations.

Folate, a water-soluble B vitamin crucial for DNA synthesis and repair, is internalized by cells through specific folate receptors (FRs), which are frequently overexpressed in various types of cancers. In this comprehensive study, we conducted a review of the literature from Google Scholar, PubMed, and Science Direct, focusing on research published between 1980 and 2024 to evaluate folate-targeted therapeutic strategies in oncology. Our study design involved a rigorous review of both preclinical and clinical research, emphasizing strategies such as folate-drug conjugates, antibody-drug conjugates, and folate-targeted nanoparticles. Key findings indicate that targeting FRs in cancers such as ovarian, breast, cervical, renal, and colorectal enhances drug delivery specificity to tumors, increases therapeutic efficacy, and decreases systemic toxicity compared to traditional chemotherapy. Several clinical trials reported improved progression-free survival and overall response rates among patients receiving folate-targeted therapies. In conclusion, our review highlights the significant potential of folate-targeted strategies in advancing precision oncology while these approaches provide substantial benefits in terms of efficacy and safety, further research is essential to refine drug design and expand clinical applications. Such initiatives will facilitate the development of more personalized cancer treatment protocols that maximize therapeutic outcomes while minimizing adverse effects.

This study examines the effects of a dietary and physical activity intervention on body composition and metabolic parameters in Moroccan women with breast cancer. Conducted as a pilot cohort study, 37 women with breast cancer were recruited between 2017 and 2019 at the Hassan II Regional Hospital Center and the Agadir Regional Oncology Center. Participants completed a 12-month nutrition and physical activity intervention. The mean age was 47.92 ± 8.56 years. At the end of the intervention, participants experienced a mean weight loss of 11%, resulting in a significant reduction in normal weight and obesity rates from 35.14% and 32.43% to 57% and 5%, respectively (p < 0.05). Waist and hip circumferences were reduced by 10%, and there were significant reductions in body fat and visceral fat. Improvements were also seen in metabolic markers, with significant reductions in total cholesterol, LDL-C, blood glucose and HbA1c levels (p < 0.05). Lean mass was preserved and HDL-C showed a significant increase (p < 0.001).

This study aimed to evaluate the relationship between the consumption of different dietary fatty acids and the risk of bladder cancer. A quantitative analysis was conducted using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which included 101,731 participants. The Cox proportional hazards model was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for bladder cancer risk in relation to dietary fatty acid intake. During a median follow-up of 11.3 years, 861 bladder cancer cases were identified. After fully adjusting for potential confounders in a multivariate Cox regression model, no significant association was found between dietary fatty acid consumption and bladder cancer risk. Subgroup analysis revealed significant interactions with gender (p < 0.001) and smoking status (p < 0.001). Gender-specific analysis showed that a higher intake of monounsaturated fatty acids (MUFAs) was linked to a reduced risk of bladder cancer in females (HR: 0.62; 95% CI: 0.39-0.99, P-trend = 0.028). However, restricted cubic spline analysis revealed no linear relationship between MUFA intake and bladder cancer risk in the overall group or gender-specific subgroups. The association between dietary fatty acids and bladder cancer risk is influenced by factors like gender and smoking status. In females, moderate MUFA intake may reduce bladder cancer risk, but higher intake does not provide additional benefits.

Background: Ovarian cancer is a lethal female cancer with a rising incidence that is often diagnosed late due to a lack of symptoms, affecting survival and quality of life. Studies suggest that dietary factors, especially the levels of branched-chain amino acids such as valine, may influence its development. While valine is essential for metabolism, its specific role in ovarian cancer remains unclear, necessitating further research.

Methods: This study aimed to elucidate the causal relationship between valine and OC through a bidirectional Mendelian randomization (MR) approach. Data were sourced from the IEU OpenGWAS project, encompassing genome-wide association statistics for valine (N = 115,048) and OC (Ncase = 1,218, Ncontrol = 198,523) among European participants. Independent genetic variants associated with each phenotype at genome-wide significance were employed as instrumental variables (IVs). The primary analysis utilized the inverse variance weighted (IVW) method for two-sample MR analysis. MR‒Egger regression was applied to adjust for potential pleiotropy, whereas the weighted median method provided robust causal estimates under the assumption of valid IVs. Sensitivity analyses, including leave-one-out (LOO) analysis, heterogeneity tests, and horizontal pleiotropy assessments, were conducted to ensure the robustness of the findings.

Results: The results revealed a significant causal relationship between valine and OC, identifying valine as a risk factor for OC (p = 0.043, 95% CI = 1.00008-1.00491, OR = 1.00249) in the forward MR analysis. Sensitivity analyses confirmed the absence of heterogeneity (Q_p value >0.05) and horizontal pleiotropy (p > 0.05), and LOO analysis validated the stability of the results. Conversely, reverse MR analysis revealed no causal effect of OC on valine levels (p = 0.875, 95% CI = 0.34125-2.51495, OR = 1.08528).

Conclusions: These findings reveal a causal link between high valine levels and an increased OC risk. This research highlights the monitoring of valine levels as a preventive strategy and the significance of valine metabolism in OC. Future studies are needed to investigate the mechanisms and interventions for reducing risk, offering insights for clinical practice and public health initiatives in OC prevention.

Objective: Identifying early predictive indicators of symptomatic hypocalcemia in patients after thyroidectomy with neck lymph node dissection can help to identify high-risk patients, provide timely intervention, and improve prognosis.

Methods: A retrospective analysis of all relevant information was conducted for patients who underwent total thyroidectomy with neck lymph node dissection at our hospital between April 2021 and September 2022. The primary outcome measure was symptomatic hypocalcemia.

Results: Of the 210 patients who underwent total thyroidectomy with l neck lymph node dissection, 76 patients (36%) experienced symptoms of hypocalcemia. The analysis confirmed that the rate of parathyroid hormone (PTH) decline (OR = 238.414, 95%CI: 51.904-1095.114, P = 0.000) was an independent risk factor for symptomatic hypocalcemia after total thyroidectomy with neck lymph node dissection. The ROC curve indicated that a PTH decline cutoff value of 0.7425 was significantly correlated with symptoms of hypocalcemia, with a sensitivity of 89% and specificity of 69%, which could effectively predict symptomatic hypocalcemia.

Conclusion: A PTH decline rate greater than the cutoff value of 0.7425 is a predictive factor for symptomatic hypocalcemia in adults and may be considered as a high-risk patient and actively managed to supplement calcium as soon as possible to ensure patient safety.

Objective: The primary objective of this investigation was to assess the impact of acupuncture intervention and explore the intricacies of acupoint selection as a therapeutic strategy for chemotherapy-induced Anorexia (CIA).

Method: Eight electronic databases were searched to identify relevant studies on the use of acupuncture for the treatment of CIA to conduct a comprehensive meta-analysis. Following this, the Apriori algorithm, correlation analysis, and cluster analysis were performed to identify correlations between the selection of acupoints.

Results: Acupuncture significantly reduced the incidence of anorexia (RR = 0.76, 95%CI: 0.65, 0.90; I²=63%; p = 0.001; n = 503) and anorexia score (SMD=-0.33, 95%CI: -0.53, -0.14; I²=22%; p = 0.0008; n = 419), as well as preserved body mass (MD = 2.70, 95%CI: 1.08, 4.32; I²=0%; p = 0.001; n = 187) and enhanced physical strength (MD = 4.23, 95%CI: 1.90, 6.55; I²=58%; p = 0.0004; n = 377). Moreover, subgroup analysis highlighted its efficacy in managing anorexia associated with non-gastrointestinal tumors and mitigating the severity of cisplatin-induced anorexia. Meanwhile, Zusanli (ST36), Neiguan (PC6), Tianshu (ST25), Zhongwan (RN12), and Qihai (RN6) were identified as crucial acupoints in CIA management.

Conclusion: Acupuncture holds promise as a potential non-pharmacological approach for managing anorexia during cancer chemotherapy. To provide robust evidence of its effectiveness, well-designed Randomized Controlled Trials (RCTs) with larger participant cohorts, and consistent core outcome measures are essential.

Aflatoxin B1 (AFB1) may be associated with not only developing liver cancer but also gallbladder cancer (GBC). We aimed to investigate whether serum AFB1 level of GBC patients is higher than chronic cholecystitis (CC) patients or healthy subjects (HS). Serum was collected from 45 GBC patients (18 men, 27 women), 57 CC patients (22 men, 35 women), and 55 HS (20 men, 35 women) from May 2021 to February 2024. Serum AFB1-lysine adduct level was measured using a commercial ELISA kit. Detection frequency (≥0.1 ng/ml), median and mean levels of serum AFB1-lysine adduct were compared among three groups. The detection rate was 71% (35/45) in GBC patients, 39% (22/57) in CC, and 7% (4/55) in HS (p < 0.001). Age- and gender-adjusted odds ratios of AFB1 detection in GBC patients were 4.1 and 16.8 times higher than in CC patients and HS, respectively. The median levels were 5.0 ng/mL in GBC patients and < 0.1 ng/mL in CC patients and HS. The mean level in GBC patients (7.9 ± 8.4 ng/mL) was significantly higher than that in CC patients (2.7 ± 4.5 ng/mL) or HS (0.3 ± 1.1 ng/mL). Our findings show direct evidence that AFB1 exposure may be associated with risk of developing GBC in India.

Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant stromal cells in the bladder cancer (BC) microenvironment (TME). However, the detailed mechanisms underlying TAM-CAF communication and their contributions to BC progression remain incompletely understood. Emerging evidence shows that Emodin exerts anti-tumor effect on several tumor models by targeting TME. To date, the impact of Emodin on BC has not been previously reported. Our study firstly demonstrated that Emodin significantly inhibited tumor growth and reduced TAM accumulation in a murine BC model. Emodin markedly decreased serum levels of multiple chemokines in tumor-bearing mice, with CXCL1 showing the most pronounced reduction. Strikingly, Emodin selectively suppressed CXCL1 secretion in CAFs but not in TAMs or tumor cells. Furthermore, the decrease in TAM migration induced by Emodin was dependent on CAF-derived CXCL1. Using a subcutaneous tumor model, we found that Emodin failed to inhibit tumor growth when CXCL1-deficient CAFs were co-injected with tumor cells, underscoring the critical role of CXCL1 in this process. Bioinformatics analysis further revealed that elevated CXCL1 levels correlated negatively with invasive/metastatic potential and overall survival in BC patients. In conclusion, our findings establish that Emodin delays BC progression by disrupting CXCL1-mediated crosstalk between CAFs and TAMs.

Breast cancer (BC) is listed as the most prevalent cancer form in women worldwide, with major subtypes classified by hormone receptor (HR) and HER2 status including, HR+/HER2- (∼65-70%), HER2+ (∼15-20%), Triple-Negative-HR-/HER2- (∼10-15%) and rare sybtypes (<5%). Scientific evidence has revealed that PI3K/AKT/mTOR signaling cascade plays an important role in the development and progression of BC, contributing to key cellular processes including cell growth, proliferation, angiogenesis, and metastasis. Dysregulation of the components of this cascade including functional loss of Phosphatase and TENsin homolog (PTEN), PI3K hyperactivation, and gain-of-function of AKT, are frequently observed in BC subtypes, making it a promising target for therapeutic intervention. A myriad of studies have documented the potential of phytochemicals, including curcumin, chrysin, fisetin, genistein, resveratrol and lycopene as modulators of the PI3K/AKT/mTOR axis. These phytochemicals exhibit multifaceted mechanisms of action, including inhibition of key kinases, induction of apoptosis, suppression of angiogenesis, and reversal of resistance to chemotherapy. This review aims to provide a detailed overview about the role of PI3K/AKT/mTOR alteration in BC development and the current research on phytochemicals that modulate the PI3K/AKT/mTOR pathway in BC. We documented the molecular mechanisms through which these compounds exert their effects, their potential synergistic interactions with conventional therapies, and the challenges and prospects for their clinical application. The evidence presented underscores the promise of phytochemicals as novel, less toxic adjuncts to traditional BC therapies, warranting further exploration and development for clinical use.